Mesa Highlights Guideline Updates in Myeloproliferative Neoplasms
October 11th 2017The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.
Dr. Maloney on Challenges With CAR T-Cell Therapy in ALL
October 10th 2017David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of CAR T-cell therapy in acute lymphocytic leukemia.
New AML Drugs Approved and Under Investigation in 2017
After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.
Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML
October 8th 2016Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).
Dr. Richard M. Stone on the Genetic Landscape in AML
October 6th 2016Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma
October 5th 2016Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.
Dr. William Wierda on Role for Ibrutinib in Frontline CLL
October 3rd 2016William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.
Dr. Steven Coutre on Frontline Treatment Decisions in CLL
October 2nd 2016Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).